Bioavailability Contract Manufacturing Development Drug Delivery Systems 
Roots Analysis
FEBRUARY 20, 2022
In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization. Nanoparticles Contract Manufacturing.
Roots Analysis
MARCH 13, 2022
Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. The Evolving Landscape of Biopharmaceutical Excipient Manufacturing Domain. Biopharmaceutical excipients can range from simple inert entities to complex compounds.
Expert insights. Personalized for you.
52 
Let's personalize your content